Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis.
D000328:Adult; D000917:Antibody Formation / Q000187:drug effects*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D014890:Granulomatosis with Polyangiitis / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D006968:Hypersensitivity, Delayed; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007136:Immunoglobulins / Q000032:analysis; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010306:Parotid Gland / Q000378:metabolism
D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide